UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Image Processing and Acquisition using Python

2, 2020

Volltextzugriff (PDF)

Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign

Journal of gastroenterology and hepatology, 2021-06, Vol.36 (6), p.1390-1390

2021

Volltextzugriff (PDF)

Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study

The lancet respiratory medicine, 2020-02, Vol.8 (2), p.171-181

2020

Volltextzugriff (PDF)

Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response

Internal medicine journal, 2015-02, Vol.45 (2), p.170-177

2015

Volltextzugriff (PDF)

Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients

Internal medicine journal, 2015-06, Vol.45 (6), p.659-666

2015

Volltextzugriff (PDF)

Conflict of interest: real and perceived - a more mature consideration is needed

Internal medicine journal, 2016-03, Vol.46 (3), p.377-379

2016

Volltextzugriff (PDF)

P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn’s disease – a meta-analysis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i694-i695

2023

Volltextzugriff (PDF)

DOP06 Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i81-i82

2024

Volltextzugriff (PDF)

P656 Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn’s disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i784-i784

2023

Volltextzugriff (PDF)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study

BMJ open respiratory research, 2019, Vol.6 (1), p.e000443-e000443

2019

Volltextzugriff (PDF)

P872 PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis – A Randomised Controlled Trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1611-i1611

2024

Volltextzugriff (PDF)

P962 Clinical and endoscopic remission at 3 months after Acute Severe Ulcerative Colitis is predictive of maintenance therapy outcomes at 12 months - Results from PREDICT UC

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1748-i1748

2024

Volltextzugriff (PDF)

Compassionate access anti‐tumour necrosis factor‐α therapy for ulcerative colitis in A ustralia: the benefits to patients

Internal medicine journal, 2015-06, Vol.45 (6), p.659-666

2015

Volltextzugriff (PDF)

Dose tailoring of anti‐tumour necrosis factor‐alpha therapy delivers useful clinical efficacy in C rohn disease patients experiencing loss of response

Internal medicine journal, 2015-02, Vol.45 (2), p.170-177

2015

Volltextzugriff (PDF)

P346 Short term dose tailoring of anti TNF-α therapy delivers useful clinical efficacy in Crohn's disease patients with secondary loss of response

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S209-S209

2014

Volltextzugriff (PDF)

P529 Compassionate access use of anti-TNF therapy in ulcerative colitis in six Australian IBD centres has been beneficial to patient outcomes

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S288-S288

2014

Volltextzugriff (PDF)

Deformity Correction with Interbody Fusion Using Lateral versus Posterior Approach in Adult Degenerative Scoliosis: A Systematic Review and Observational Meta-analysis

Asian spine journal, 2023-04, p.431-451

2023

Volltextzugriff (PDF)

Safety comparison of therapies used in inflammatory bowel disease

Journal of gastroenterology and hepatology, 2021-04, Vol.36 (S1), p.20-21

Pudipeddi, Aviv

2021

Volltextzugriff (PDF)

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Therapeutic advances in gastroenterology, 2022-03, Vol.15, p.17562848221080793-17562848221080793

2022

Volltextzugriff (PDF)

Su1512: UTILISATION AND IMPACT OF IMMUNOMODULATOR CO-THERAPY WITH FIRST-LINE AND SECOND-LINE ANTI-TUMOUR NECROSIS FACTOR AGENTS IN CROHNS DISEASE AND ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-608-S-608

2022

Volltextzugriff (PDF)

Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study

The American journal of gastroenterology, 2024-08, Vol.119 (8), p.1536-1544

2024

Volltextzugriff (PDF)

Gastroenterologists’ preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey

European journal of gastroenterology & hepatology, 2020-08, Vol.32 (8), p.976-983

2020

Volltextzugriff (PDF)

Trends in Solubility of Polymorphs

Journal of pharmaceutical sciences, 2005-05, Vol.94 (5), p.929-939

2005

Volltextzugriff (PDF)

Image Processing and Acquisition using Python, 2nd Edition

2020

Volltextzugriff (PDF)

Combination Therapy of Immunomodulators With Non–Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?

Clinical gastroenterology and hepatology, 2022-03, Vol.20 (3), p.e640-e641

2022

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(123)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Image Processing and Acquisition using Python

Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign

Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study

Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response

Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients

Conflict of interest: real and perceived - a more mature consideration is needed

P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn’s disease – a meta-analysis

DOP06 Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab

P656 Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn’s disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study

P872 PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis – A Randomised Controlled Trial

P962 Clinical and endoscopic remission at 3 months after Acute Severe Ulcerative Colitis is predictive of maintenance therapy outcomes at 12 months - Results from PREDICT UC

Compassionate access anti‐tumour necrosis factor‐α therapy for ulcerative colitis in A ustralia: the benefits to patients

Dose tailoring of anti‐tumour necrosis factor‐alpha therapy delivers useful clinical efficacy in C rohn disease patients experiencing loss of response

P346 Short term dose tailoring of anti TNF-α therapy delivers useful clinical efficacy in Crohn's disease patients with secondary loss of response

P529 Compassionate access use of anti-TNF therapy in ulcerative colitis in six Australian IBD centres has been beneficial to patient outcomes

Deformity Correction with Interbody Fusion Using Lateral versus Posterior Approach in Adult Degenerative Scoliosis: A Systematic Review and Observational Meta-analysis

Safety comparison of therapies used in inflammatory bowel disease

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Su1512: UTILISATION AND IMPACT OF IMMUNOMODULATOR CO-THERAPY WITH FIRST-LINE AND SECOND-LINE ANTI-TUMOUR NECROSIS FACTOR AGENTS IN CROHNS DISEASE AND ULCERATIVE COLITIS

Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study

Gastroenterologists’ preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey

Trends in Solubility of Polymorphs

Image Processing and Acquisition using Python, 2nd Edition

Combination Therapy of Immunomodulators With Non–Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?

Suchergebnisse filtern